Surgically resectable nonsmall cell lung cancer: a contemporary approach.

New treatment paradigms for resectable nonsmall cell lung cancer (NSCLC), with an emphasis on personalised care and a multidisciplinary approach, have significantly improved patient outcomes. The incorporation of immune checkpoint inhibitors into neoadjuvant, perioperative and adjuvant treatment algorithms is reshaping the standard of care for resectable NSCLC. Adjuvant targeted therapy trials have also paved the way for a much-needed personalised approach for patients with actionable genomic alterations. Innovative surgical techniques and judicious use of postoperative radiotherapy may mitigate the toxicity associated with a multimodality approach. Amid the many new treatment options, questions remain about the best approach to consider for each patient. Measurement of minimal residual disease and achievement of pathological complete response are emerging biomarkers of interest to help further refine treatment selection. This review summarises the current management of resectable NSCLC, focusing on ongoing and recent advances in surgical approaches, the role of postoperative radiotherapy and the rapidly changing field of systemic therapies.
Competing Interests: Conflict of interest: M-F. D'Amours has received honoraria for an educational presentation from Pfizer. C. Ho has received research grants from AstraZeneca and Roche; and honoraria for advisory boards from Abbvie, Amgen, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Janssen, Jazz, Merck, Novartis, Pfizer, Roche, Sanofi and Takeda. F.T.H. Wu has received honoraria for an educational presentation from Bristol Myers Squibb. A. McGuire has received an educational grant from Johnson & Johnson; and honoraria for advisory boards from AstraZeneca, Bristol Myers Squibb and Medtronic. The remaining authors have no potential conflicts of interest to disclose.
(Copyright ©The authors 2024. For reproduction rights and permissions contact permissions@ersnet.org.)